Caribou Biosciences looked to have streaked into the lead in the off-the-shelf CAR-T field last month with a 100% complete response rate in its first five evaluable patients, but updated results from the Phase I ANTLER study suggest its candidate, CB-010 suffers from similar durability of response problems to its rivals.
The eye-catching 100% complete response rate in relapsed or refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL) patients was presented in Caribou’s abstract ahead of the European Hematology Association (EHA) congress, and...